1,333 Shares in Johnson & Johnson (NYSE:JNJ) Acquired by DE Burlo Group Inc.

DE Burlo Group Inc. acquired a new position in Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,333 shares of the company’s stock, valued at approximately $216,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new position in Johnson & Johnson in the 1st quarter worth $765,000. Canada Pension Plan Investment Board boosted its position in shares of Johnson & Johnson by 25.3% in the first quarter. Canada Pension Plan Investment Board now owns 3,487,163 shares of the company’s stock worth $551,634,000 after purchasing an additional 703,158 shares during the period. Stonebridge Capital Advisors LLC boosted its position in shares of Johnson & Johnson by 10.0% in the first quarter. Stonebridge Capital Advisors LLC now owns 105,170 shares of the company’s stock worth $16,637,000 after purchasing an additional 9,556 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. boosted its position in shares of Johnson & Johnson by 33.3% during the first quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 2,000 shares of the company’s stock worth $316,000 after acquiring an additional 500 shares during the last quarter. Finally, Truvestments Capital LLC boosted its position in shares of Johnson & Johnson by 8.4% during the first quarter. Truvestments Capital LLC now owns 21,805 shares of the company’s stock worth $3,449,000 after acquiring an additional 1,690 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on JNJ shares. Wolfe Research started coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Royal Bank of Canada boosted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Finally, Morgan Stanley upped their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $175.94.

Johnson & Johnson Trading Up 0.1 %

Shares of JNJ stock opened at $153.10 on Thursday. The company has a 50-day moving average of $160.59 and a two-hundred day moving average of $156.17. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The firm has a market cap of $368.59 billion, a PE ratio of 22.16, a price-to-earnings-growth ratio of 2.72 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter last year, the company earned $2.66 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.